Literature DB >> 315841

Circulating immune complexes in patients with cryptogenic fibrosing alveolitis.

P L Haslam, B Thompson, I Mohammed, P J Townsend, M E Hodson, E J Holborow, M Turner-Warwick.   

Abstract

Increased Clq binding levels have been obtained in serum from twenty-one (50%) of forty-two patients with cryptogenic fibrosing alveolitis (CFA) suggesting the presence of circulating immune complexes. There was a low frequency of positive results using a number of other tests for circulating immune complexes. The increased Clq binding levels were observed in six (35%) out of seventeen patients with lone lung involvement and in fifteen (60%) out of twenty-five patients with extrapulmonary connective tissue disorders. There was an especially close correlation between arthritis and elevated Clq binding. A strong correlation between Clq binding levels and levels of circulating rheumatoid factor (RF) and IgG, and enhancement in macrophage radiobioassay tests using RF-containing sera, suggested that RF might be involved in the circulating immune complexes in these patients. DNAase pre-treatment of sera did not influence the findings, and there was no correlation between Clq binding and levels of immunofluorescent ANA, C-reactive protein levels, or platelet counts. A weak correlation between Clq binding and erythrocyte sedimentation rates, and slightly lower binding levels in treated than untreated patients with 'lone' CFA suggested that binding levels may give some indication of disease activity and may in some instances be influenced by treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315841      PMCID: PMC1537788     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Interactions of C-reactive protein with the first component of human complement.

Authors:  D R Claus; J Siegel; K Petras; A P Osmand; H Gewurz
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

2.  FIBROSING ALVEOLITIS.

Authors:  J G SCADDING
Journal:  Br Med J       Date:  1964-09-12

3.  AUTO-ANTIBODY STUDIES IN INTERSTITIAL PULMONARY FIBROSIS.

Authors:  M TURNER-WARWICK; D DONIACH
Journal:  Br Med J       Date:  1965-04-03

4.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

Review 5.  Morphology and pathogenesis of desquamative interstitial pneumonitis.

Authors:  E Valdivia; G Hensley; E P Leory; J Wu; W Jaeschke
Journal:  Thorax       Date:  1977-02       Impact factor: 9.139

6.  Characterization of antibodies to the native human collagens and to their component alpha chains in the sera and the joint fluids of patients with rheumatoid arthritis.

Authors:  N A Andriopoulos; J Mestecky; G P Wright; E J Miller
Journal:  Immunochemistry       Date:  1976-08

Review 7.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects.

Authors:  R G Crystal; J D Fulmer; W C Roberts; M L Moss; B R Line; H Y Reynolds
Journal:  Ann Intern Med       Date:  1976-12       Impact factor: 25.391

8.  Circulating immune complexes in the idiopathic interstitial pneumonias.

Authors:  R B Dreisin; M I Schwarz; A N Theofilopoulos; R E Stanford
Journal:  N Engl J Med       Date:  1978-02-16       Impact factor: 91.245

9.  Demonstration of antibodies to collagen and of collagen-anticollagen immune complexes in rheumatoid arthritis synovial fluids.

Authors:  J Menzel; C Steffen; G Kolarz; G Eberal; O Frank; N Thumb
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

10.  Pathogenic mechanisms in pulmonary fibrosis: collagen-induced migration inhibition factor production and cytotoxicity mediated by lymphocytes.

Authors:  T C Kravis; A Ahmed; T E Brown; J D Fulmer; R G Crystal
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

View more
  19 in total

1.  Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?

Authors:  R Meliconi; E Lalli; R M Borzì; C Sturani; V Galavotti; G Gunella; R Miniero; A Facchini; G Gasbarrini
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

2.  Expression of class II MHC antigens on alveolar epithelium in fibrosing alveolitis.

Authors:  C G Kallenberg; B M Schilizzi; F Beaumont; S Poppema; L De Leij; T H The
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

3.  Cutaneous vasculitis and immune complexes in severe bronchiectasis.

Authors:  A M Hilton; P S Hasleton; A Bradlow; B C Leahy; K M Cooper; M Moore
Journal:  Thorax       Date:  1984-03       Impact factor: 9.139

4.  Fall in immune complex levels during gold treatment of rheumatoid arthritis.

Authors:  J Highton; G S Panayi; P Shepherd; A Faith; J Griffin; T Gibson
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

5.  Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy.

Authors:  P L Haslam; C W Turton; A Lukoszek; A J Salsbury; A Dewar; J V Collins; M Turner-Warwick
Journal:  Thorax       Date:  1980-05       Impact factor: 9.139

6.  Impaired antibody-dependent cell-mediated cytotoxicity in cryptogenic fibrosing alveolitis (synonym: idiopathic pulmonary fibrosis).

Authors:  P L Haslam; F Allan; A F Watling; C Barrett; L Morris; M Turner-Warwick
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

7.  Time course of bleomycin-induced lung fibrosis.

Authors:  G Izbicki; M J Segel; T G Christensen; M W Conner; R Breuer
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

8.  Detection of anti-cytokeratin 8 antibody in the serum of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis associated with collagen vascular disorders.

Authors:  N Dobashi; J Fujita; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Kamei; M Tokuda; S Hojo; H Okada; J Takahara
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

9.  Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis.

Authors:  W A Wallace; S N Roberts; H Caldwell; E Thornton; A P Greening; D Lamb; S E Howie
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

10.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.